Skip to main content
. 2021 Nov 9;60:255–262. doi: 10.1016/j.breast.2021.11.004

Table 2.

Risk classification by genetic platforms.

Genetic test n (%) Risk classification
OncotypeDx® (49%) RS low (62,7%)
RS intermédiate (27,7%)
RS high (9,5%)
Mammaprint® (51%) High (38,4%)
Low (61,6%)